• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ASTRO ’17 Round-up: Novocure touts five-year results for Optune, chemo combo in newly-diagnosed glioblastoma patients

September 25, 2017 By Sarah Faulkner

Immunotherapy, radiation therapy triggers favorable response in patients with late-stage cancer

ASTROA Phase II trial presented today at ASTRO showed that patients with stage IV cancer that had spread to the lungs or liver had a favorable response to treatment with radiation therapy and immunotherapy.

“This combination of immunotherapy and radiation therapy was safe and well-tolerated by patients with late-stage cancers. We were surprised that a large percentage of patients achieved stable disease several months after treatment—meaning that while their tumors didn’t shrink, they did stop growing,” lead author Dr. James Welsh said in prepared remarks.

“It appears that the radiation helped turn the tumor into a vaccine to stimulate an immune response. This heightened immune response was able to keep the tumors stable. Longer follow-up is needed to determine if this benefit of stable disease will endure over time.”

The Phase II trial enrolled 100 patients to evaluate the combination of high-dose radiation therapy and immunotherapy.

The whole group of patients received four cycles of ipilimumab and stereotactic body radiation therapy to the site or sites of metastasis in either the liver or the lungs. Randiation therapy was given either concurrently with or sequentially to immunotherapy, the researchers noted.

Patients were enrolled into one of five cohorts: concurrent lung, sequential-Gy lung, concurrent liver, sequential 50-Gy liver and sequential 60-Gy liver or lung.

Half of the patients in the sequential 50-Gy lung cohort experienced disease stability, as well as 45% of the concurrent-lung group, 35% of the concurrent liver group and 30% of the sequential 50-Gy liver group. In the larger-lesion, higher-dose radiation group, 60% of patients had a favorable response to treatment.

Median progression-free survival for all patients following radiation therapy combined with immunotherapy was five months and median overall survival was 12 months.

There were no complete responses to treatment, the researchers reported, but three patients who received SBRT concurrently with immunotherapy had a partial response.

“A small percentage of patients experienced a potential abscopal effect, where tumors that were not irradiated became smaller after we treated different sites with radiation,”Welsh said. “For example, one patient with anaplastic thyroid cancer—one of the deadliest types of cancer—experienced a reduction in the primary tumor after we irradiated a lung metastasis. This patient had controlled disease for more than 13 months.

“We found that the addition of SBRT for patients who are on immunotherapy to be safe and well-tolerated, meaning that radiation oncologists can feel confident continuing immunotherapy for most patients when adding SBRT to lung or liver metastases. In fact, there may be additional benefit from combining the therapies in terms of improved disease control. Follow-up research in larger clinical trials is needed to determine which types of tumors and patients will respond best to this immunotherapy-radiation approach.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Mayo Clinic, NovoCure, Royal Philips, viewray

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS